Zohydro ban in Mass. blocked by federal judge

Zohydro ban: Massachusetts Governor Deval Patrick said he was disappointed, arguing that the ruling places commercial interests above the public's health.

|
Charles Krupa/AP/File
Mass. Gov. Deval Patrick gestures during a news conference at the Statehouse in Boston. Patrick last week ordered an outright ban on prescribing and dispensing Zohydro until it is marketed in a form that is difficult to abuse.

A federal judge has blocked Massachusetts from banning the powerful new painkiller Zohydro.

U.S. District Court Judge Rya Zobel on Tuesday issued a preliminary injunction after the maker of the drug, Zogenix, argued in a lawsuit that the ban ordered by Gov. Deval Patrick last month is unconstitutional.

Zobel said in issuing the injunction that Massachusetts appears to have overstepped its authority in banning the prescription medication, which had been approved by the federal Food and Drug Administration, and that Zogenix was likely to succeed in its pursuit of a court order to lift the ban permanently.

The San Diego-based drugmaker hailed the ruling, saying that allowing states to essentially overturn decisions of the FDA would "set an alarming precedent."

Patrick said he was disappointed, arguing that the ruling places commercial interests above the public's health.

"Addiction is a serious enough problem already in Massachusetts without having to deal with another addictive narcotic painkiller sold in a form that isn't tamper proof," Patrick said in a statement. "We will turn our attention now to other means to address this public health crisis."

The ban is believed to be the first attempt by a state to block a federally approved drug, according to the National Alliance for Model State Drug Laws.

Patrick ordered the ban after declaring a public health emergency in light of a surge of drug overdoses and overdose deaths in the state. The state argued that Zohydro would "exacerbate a severe public health crisis" because the narcotic can be easily crushed, then snorted or injected to create an immediate and potentially lethal high.

In her decision, Zobel noted the FDA's approval of the drug in October and said federal law pre-empts Patrick's emergency order.

"When the Commonwealth interposed its own conclusion about Zohydro ER's safety and effectiveness by virtue of the ... emergency order, did it obstruct FDA's Congressionally-given charge? I conclude that it did," Zobel wrote.

She said allowing the ban would "undermine the FDA's ability to make drugs available to promote and protect the public health." She said Patrick's suggestion that the ban might be lifted if Zogenix created a non-crushable "abuse-resistant" version of the prescription medication would force Zogenix to return to the FDA to seek approval for a drug different from the one that the FDA has already deemed safe.

Zogenix has also been able to show injury to its reputation by the highly publicized ban, Zobel said.

The judge said the state's concerns can't trump the legitimate use of the drug.

"Although the ban may prevent someone from misusing the drug, the ban prevents all in need of its special attributes from receiving the pain relief Zohydro ER offers," she wrote.

Roger Hawley, chief executive officer of Zogenix, called the decision "a positive step forward for Massachusetts patients."

"We invite concerned officials to engage with us to discuss fair and appropriate safeguards for pain medications like ZohydroER rather than seeking to ban or restrict one specific treatment," Hawley said in a written statement.

Lawyers for the state had argued that the Massachusetts ban wouldn't affect the federal approval process or the company's ability to sell the drug elsewhere in the United States, but simply represented "another hurdle" the company must surpass in order to market the drug in Massachusetts.

You've read  of  free articles. Subscribe to continue.
Real news can be honest, hopeful, credible, constructive.
What is the Monitor difference? Tackling the tough headlines – with humanity. Listening to sources – with respect. Seeing the story that others are missing by reporting what so often gets overlooked: the values that connect us. That’s Monitor reporting – news that changes how you see the world.

Dear Reader,

About a year ago, I happened upon this statement about the Monitor in the Harvard Business Review – under the charming heading of “do things that don’t interest you”:

“Many things that end up” being meaningful, writes social scientist Joseph Grenny, “have come from conference workshops, articles, or online videos that began as a chore and ended with an insight. My work in Kenya, for example, was heavily influenced by a Christian Science Monitor article I had forced myself to read 10 years earlier. Sometimes, we call things ‘boring’ simply because they lie outside the box we are currently in.”

If you were to come up with a punchline to a joke about the Monitor, that would probably be it. We’re seen as being global, fair, insightful, and perhaps a bit too earnest. We’re the bran muffin of journalism.

But you know what? We change lives. And I’m going to argue that we change lives precisely because we force open that too-small box that most human beings think they live in.

The Monitor is a peculiar little publication that’s hard for the world to figure out. We’re run by a church, but we’re not only for church members and we’re not about converting people. We’re known as being fair even as the world becomes as polarized as at any time since the newspaper’s founding in 1908.

We have a mission beyond circulation, we want to bridge divides. We’re about kicking down the door of thought everywhere and saying, “You are bigger and more capable than you realize. And we can prove it.”

If you’re looking for bran muffin journalism, you can subscribe to the Monitor for $15. You’ll get the Monitor Weekly magazine, the Monitor Daily email, and unlimited access to CSMonitor.com.

QR Code to Zohydro ban in Mass. blocked by federal judge
Read this article in
https://www.csmonitor.com/USA/Latest-News-Wires/2014/0416/Zohydro-ban-in-Mass.-blocked-by-federal-judge
QR Code to Subscription page
Start your subscription today
https://www.csmonitor.com/subscribe